{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:45:39Z","timestamp":1787165139162,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00818-7","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:54:31Z","timestamp":1758272071000},"page":"2313-2325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty"],"prefix":"10.1007","volume":"14","author":[{"given":"Gina","family":"Ferrazzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom","family":"Haggiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriana","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Buscarinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Malimpensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Borriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Barbuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Marchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Leodori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Belvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Buttari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cicia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolama Alessandra","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"10","key":"818_CR1","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394. https:\/\/doi.org\/10.1007\/s00415-022-11193-w.","journal-title":"J Neurol"},{"issue":"4","key":"818_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/wnl.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907\u201311. https:\/\/doi.org\/10.1212\/wnl.46.4.907.","journal-title":"Neurology"},{"issue":"12","key":"818_CR3","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380\u201313902. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049.","journal-title":"Am J Med"},{"issue":"9","key":"818_CR4","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/1352458516675039","volume":"23","author":"A Kavaliunas","year":"2017","unstructured":"Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedstr\u00f6m AK, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler. 2017;23(9):1233\u201340. https:\/\/doi.org\/10.1177\/1352458516675039.","journal-title":"Mult Scler"},{"issue":"10","key":"818_CR5","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/ene.13692","volume":"25","author":"TA Chalmer","year":"2018","unstructured":"Chalmer TA, Baggesen LM, N\u00f8rgaard M, Koch-Henriksen N, Magyari M, Sorensen PS, Danish Multiple Sclerosis Group. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol. 2018;25(10):1262\u20132110. https:\/\/doi.org\/10.1111\/ene.13692.","journal-title":"Eur J Neurol"},{"key":"818_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.595547","volume":"11","author":"CA Roach","year":"2021","unstructured":"Roach CA, Cross AH. Anti-CD20 B cell treatment for relapsing multiple sclerosis. Front Neurol. 2021;11: 595547. https:\/\/doi.org\/10.3389\/fneur.2020.595547.","journal-title":"Front Neurol"},{"issue":"18","key":"818_CR7","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/cer-2020-0122","volume":"9","author":"IA Samjoo","year":"2020","unstructured":"Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, H\u00e4ring DA, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255\u201374. https:\/\/doi.org\/10.2217\/cer-2020-0122.","journal-title":"J Comp Eff Res"},{"issue":"6","key":"818_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al, ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"issue":"1","key":"818_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","volume":"177","author":"JL Teeling","year":"2006","unstructured":"Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362\u201371. https:\/\/doi.org\/10.4049\/jimmunol.177.1.362. (PMID: 16785532).","journal-title":"J Immunol"},{"issue":"10","key":"818_CR10","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/13524585221078825","volume":"28","author":"J G\u00e4rtner","year":"2022","unstructured":"G\u00e4rtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II. Mult Scler. 2022;28(10):1562\u201375. https:\/\/doi.org\/10.1177\/13524585221078825.","journal-title":"Mult Scler"},{"issue":"1","key":"818_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/17582024.2025.2452150","volume":"15","author":"M Amin","year":"2025","unstructured":"Amin M, Harvey T, Pineda DM, Tai MH, Shao Q, Brown B, et al. Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. Neurodegener Dis Manag. 2025;15(1):27\u201336. https:\/\/doi.org\/10.1080\/17582024.2025.2452150.","journal-title":"Neurodegener Dis Manag"},{"issue":"9","key":"818_CR12","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1007\/s00415-024-12581-0","volume":"271","author":"AS Karl","year":"2024","unstructured":"Karl AS, Klimas R, Katsimpoura M, Sgodzai M, Theile-Ochel S, Poser PL, et al. Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study. J Neurol. 2024;271(9):6080\u20138. https:\/\/doi.org\/10.1007\/s00415-024-12581-0.","journal-title":"J Neurol"},{"issue":"7","key":"818_CR13","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2468-2667(18)30091-4","volume":"3","author":"P Hanlon","year":"2018","unstructured":"Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493\u2008737 UK Biobank participants. Lancet Public Health. 2018;3(7):e323\u201332. https:\/\/doi.org\/10.1016\/S2468-2667(18)30091-4.","journal-title":"Lancet Public Health"},{"issue":"7","key":"818_CR14","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/brain\/awz144","volume":"142","author":"M Filippi","year":"2019","unstructured":"Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. 2019;142(7):1858\u201375. https:\/\/doi.org\/10.1093\/brain\/awz144.","journal-title":"Brain"},{"issue":"2","key":"818_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"issue":"11","key":"818_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"key":"818_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1100\/tsw.2001.58","volume":"1","author":"AB Mitnitski","year":"2001","unstructured":"Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. Sci World J. 2001;1:323\u201336. https:\/\/doi.org\/10.1100\/tsw.2001.58.","journal-title":"Sci World J"},{"key":"818_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-8-24","volume":"8","author":"SD Searle","year":"2008","unstructured":"Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8: 24. https:\/\/doi.org\/10.1186\/1471-2318-8-24.","journal-title":"BMC Geriatr"},{"issue":"7","key":"818_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271688","volume":"17","author":"T Zanotto","year":"2022","unstructured":"Zanotto T, Rice LA, Sosnoff JJ. Frailty among people with multiple sclerosis who are wheelchair users. PLoS ONE. 2022;17(7): e0271688. https:\/\/doi.org\/10.1371\/journal.pone.0271688.","journal-title":"PLoS ONE"},{"issue":"12","key":"818_CR20","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1177\/1352458520987541","volume":"27","author":"D Belvisi","year":"2021","unstructured":"Belvisi D, Canevelli M, Baione V, Buscarinu MC, Pellicciari G, Fantozzi R, et al. Operationalization of a frailty index in patients with multiple sclerosis: a cross-sectional investigation. Mult Scler. 2021;27(12):1939\u201347. https:\/\/doi.org\/10.1177\/1352458520987541.","journal-title":"Mult Scler"},{"issue":"11\u201312","key":"818_CR21","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/13524585231195346","volume":"29","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Zielman R, Das Gupta A, Xi J, Stoneman D, Karlsson G, et al. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension. Mult Scler. 2023;29(11\u201312):1452\u201364. https:\/\/doi.org\/10.1177\/13524585231195346.","journal-title":"Mult Scler"},{"issue":"7","key":"818_CR22","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00415-024-12360-x","volume":"271","author":"A Zangh\u00ec","year":"2024","unstructured":"Zangh\u00ec A, Borriello G, Bonavita S, Fantozzi R, Signoriello E, Barone S, et al. Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study. J Neurol. 2024;271(7):4495\u2013502. https:\/\/doi.org\/10.1007\/s00415-024-12360-x.","journal-title":"J Neurol"},{"issue":"3","key":"818_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.27143","volume":"97","author":"SG Meuth","year":"2025","unstructured":"Meuth SG, Wolff S, M\u00fcck A, Willison A, Kleinschnitz K, R\u00e4uber S, et al. Different treatment outcomes of multiple sclerosis patients receiving ocrelizumab or ofatumumab. Ann Neurol. 2025;97(3):583\u201395. https:\/\/doi.org\/10.1002\/ana.27143.","journal-title":"Ann Neurol"},{"key":"818_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/2055217317715049","author":"J Correale","year":"2017","unstructured":"Correale J, Farez MF, Gait\u00e1n MI. Environmental factors influencing multiple sclerosis in Latin America. Mult Scler J. 2017. https:\/\/doi.org\/10.1177\/2055217317715049.","journal-title":"Mult Scler J"},{"issue":"8","key":"818_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/1352458519886943","volume":"26","author":"R Milo","year":"2020","unstructured":"Milo R, Korczyn AD, Manouchehri N, St\u00fcve O. The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis. Mult Scler. 2020;26(8):876\u201386. https:\/\/doi.org\/10.1177\/1352458519886943.","journal-title":"Mult Scler"},{"issue":"2","key":"818_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","volume":"14","author":"DH Mahad","year":"2015","unstructured":"Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(14)70256-X.","journal-title":"Lancet Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00818-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:45:20Z","timestamp":1763376320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00818-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00818-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, Doriana Landi, Francesca Napoli, Maria Chiara Buscarinu, Leonardo Malimpensa, Assunta Bianco, Giovanna Borriello, Elena Barbuti, Fabiana Marinelli, Fabrizia Monteleone, Francesca Marchione, Nicola Falcone, Marta Altieri, Giorgio Leodori, Daniele Belvisi, Fabio Buttari, Valeria Pozzilli, Alessandra Cicia, Antonio Cortese, Francesco Sica, Anna Chiara Landi, Elisabetta Ferraro, Carlo Pozzilli, Massimiliano Mirabella, Carla Tortorella, Girolama Alessandra Marfia, Diego Centonze, Marco Salvetti and Antonella Conte declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the local Ethics Committee of the University Hospital Policlinico Umberto I (No. 6357) on June 9, 2021. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}